If you've looked into the research on craniosacral therapy, you've probably hit a mixed picture. Some reviews are cautiously positive. Others are quite sceptical. Claims in mainstream CST literature don't always match what formal studies have found. That can be confusing, especially if you or someone you care about has had real benefit from the therapy.
The truth is the evidence for CST is neither uniformly positive nor definitively negative. It's contested. Understanding why means knowing a little about how research in this area actually works, and why different reviews can read roughly the same literature and reach quite different conclusions. None of this should put you off exploring the therapy. It's just worth having a clear picture of where the research stands.
Why different reviews reach different conclusions
Systematic reviews and meta-analyses are meant to give us a clearer picture than individual studies by pooling sources of evidence. In practice, two reviews of the same field can land in different places depending on which studies they include, what quality thresholds they apply, and which conditions they cover.
In the CST literature, this variability is especially noticeable. A 2019 meta-analysis by Jäkel and von Hauenschild looked at ten RCTs with 681 patients and found significant effects on pain and function lasting up to six months, a reasonably positive result. More recent reviews from 2024, covering larger pools of studies with tighter quality criteria, reached more cautious conclusions. That doesn't mean one is right and the other wrong. The research base has grown, methods for evaluating it have evolved, and the honest answer is still developing.
Condition selection also matters a lot. A review focused on neck pain and fibromyalgia, where there are some decent-sized trials, will look quite different from one that includes conditions where CST has been studied poorly or not at all. The 'evidence for CST' isn't one unified thing. It varies by condition, by outcome measure, and by the quality of the available trials.
The problem of small samples
Most CST trials are small. Many have fewer than 100 participants. Some have fewer than 50. This is a consistent limitation in the field, and it matters more than it might first seem.
Small trials are more likely to throw up false positives by chance. They're also less able to detect real effects that are modest in size. And when you try to draw broad conclusions across multiple small trials, the uncertainties compound. A positive result from a 54-person RCT is genuinely meaningful, but it needs to be replicated in larger studies before it can anchor a strong clinical recommendation.
This isn't unique to CST. Many areas of complementary and manual therapy have the same problem. Running large, well-funded clinical trials needs institutional support and research infrastructure that doesn't always prioritise manual therapies. The result is a literature that's fragmented, variable in quality, and hard to read as a whole.
The rhythm question is separate from whether CST helps
Some of the most pointed criticism of CST targets the foundational claim that practitioners can detect and influence a craniosacral rhythm, a subtle pulsation of the cerebrospinal fluid said to be distinct from heartbeat and breathing. Reliability studies on this aren't encouraging. Interrater reliability (whether two practitioners detect the same rhythm in the same patient at the same time) has generally been poor in controlled conditions.
This matters, but differently than it might seem. The debate about mechanism is genuinely separate from whether patients benefit. Therapies can work through mechanisms other than the ones originally proposed, and the history of medicine includes many treatments whose mechanisms were misunderstood for decades before being clarified. The scepticism about the craniosacral rhythm is worth taking seriously, but it doesn't automatically negate every positive clinical finding.
What it does mean is that CST rests on a theoretical framework that hasn't been fully validated in laboratory research. For some people, that's a significant concern. For others, the more important question is whether the therapy helps. On that, the picture is more nuanced. Many people report genuine benefit, and some conditions have encouraging if preliminary trial data. The research is still evolving, and a settled verdict either way would be premature.
The contested nature of the CST evidence isn't a reason to dismiss the therapy or to accept it uncritically. It's a reason to read what's there carefully, hold claims lightly, and stay open to an honest conversation about what is and isn't known. Many people find real value in CST, and the research is slowly, if unevenly, catching up.